Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor overview
Stock information
Press releases
Events
SEC filings
Corporate governance
Investor presentations
Investor FAQs
Email alerts

Investor contact

For investor related questions, please email

investors@aclaristx.com

Media contact
& resources »

Investor presentations

Investor presentations

Aclaris Therapeutics Company Overview

Aclaris Therapeutics Provides R&D Update on ATI-501/502 (JAK 1/3 Inhibitor) Program

Immuno-dermatology Pipeline Presentation October 2017

Genetics and Immunology of Alopecia Areata Presentation October 2017

Aclaris - Footer Menu

Terms of use
Privacy policy
Media resources
Contact us

© 2019 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.